Atara Biotherapeutics, Inc.
ATRA· Nasdaq
Released Aug 9, 2021, after the close
10-Q filed Aug 9, 2021, 40 days after period end · 0001564590-21-042636
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Net Income | -$83.79M | -$77.46M | -$74.33M | -$50.88M |
| EPS Diluted | -$0.91 | -$1.14 | -$1.60 | -$1.15 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Atara Biotherapeutics, Inc. · CIK 1604464 · Engraved from SEC EDGAR